<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81774">
  <stage>Registered</stage>
  <submitdate>22/12/2006</submitdate>
  <approvaldate>4/01/2007</approvaldate>
  <actrnumber>ACTRN12607000005459</actrnumber>
  <trial_identification>
    <studytitle>Maxi-Analgesic Junior Study</studytitle>
    <scientifictitle>Maxi-Analgesic Junior Study: Double-blind, randomized, comparison of the analgesic effect of Paracetamol and Ibuprofen Combined versus Paracetamol or Ibuprofen alone in Post Tonsillectomy Patients.</scientifictitle>
    <utrn />
    <trialacronym>AFT MX-2</trialacronym>
    <secondaryid>AFT-MX-2</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Children requiring analgesia post tonsillectomy</healthcondition>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intervention treatment:
This will be oral suspension of paracetamol 120mg+ Ibuprofen 60 mg per 5 ml and will be taken every 6 hour. The first dose will be administrated one hour before the operation and then 6 hourly up to 48 hours after the first dose. 
</interventions>
    <comparator>Control treatment:
This will be either oral suspension of paracetamol 120mg per 5 ml or ibuprofen 60mg per 5 ml. The first dose will be administrated one hour before the operation and then very 6 hour up to 48 hours after the first dose.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To compare the analgesic effects of the 3 treatment groups (paracetamol+ibuprofen, paracetamol or ibuprofen) on the time adjusted AUC (Area under the curve) of the VAS (Visual Analogue Scale) pain scores</outcome>
      <timepoint>Taken at rest from the first dose of study medication until 48 hours after the first dose.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the analgesic effects of the 3 treatment groups (paracetamol+ibuprofen, paracetamol or ibuprofen) on the time adjusted AUC of the VAS pain scores (taken on swallowing).</outcome>
      <timepoint>From the first dose of study medication until 48 hours after the first dose.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Requirement for resuce analgesia (defined by transferring patients from study medication to Maxigesic Junior or Morphine).</outcome>
      <timepoint>From the first dose of study medicine up to 48 hours after first dose.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>A categorical global pain rating assessed by patients of pain as "nil", "mild", "moderate" or "severe"</outcome>
      <timepoint>At the end of the study i.e. up to 48 hours after the first dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>A rating of sleep disturbance on a 100 mm Visual Analogue Scale</outcome>
      <timepoint>Up to 48 hours after the first dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Children requiring analgesia post tonsillectomy.</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>14</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Too young or too old.Too small (weight below 15 kg at base line visit)Having taken any NSAID or paracetamol within 12 hours prior to the operation.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>sealed opaque envelopes</concealment>
    <sequence>permuted block randomisation generated by computer</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Subjects and Investigators are blind to the treatment</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/05/2008</anticipatedstartdate>
    <actualstartdate>17/10/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>10/06/2010</actualenddate>
    <samplesize>150</samplesize>
    <actualsamplesize>152</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>12/06/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland </state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Ahmedabad</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Hartley Atkinson, Managing Director, AFT Pharmaceuticals, Ltd</primarysponsorname>
    <primarysponsoraddress>Level 2, 9 Anzac Street, Takapuna, Auckland</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>AFT (Atkinson Family Trust) Pharmaceuticals Ltd</fundingname>
      <fundingaddress>Level 2, 9 Anzac Street, Takapuna, Auckland, New Zealand</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>AFT Pharmaceuticals Ltd</fundingname>
      <fundingaddress>Level 2, 9 Anzac Street, Takapuna, Auckland</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Alan Merry, Professor, Department of Anathesiology, University of Auckland</sponsorname>
      <sponsoraddress>Ground floor, Mercy Hospital, 98-100 Mountain Road, Epsom, Auckland</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study hypothesis is that the combination of appropriate clincal doses of ibuprofen and paracetamol has greater analgesic efficacy than the same doses of either paracetamol or ibupofen alone.</summary>
    <trialwebsite />
    <publication>Randomized comparison between the combination of acetaminophen and ibuprofen and each constituent alone for analgesia following tonsillectomy in children.
Merry AF1, Edwards KE, Ahmad Z, Barber C, Mahadevan M, Frampton C.
Can J Anaesth. 2013 Dec;60(12):1180-9.
</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern X Regional Ethics Committee</ethicname>
      <ethicaddress>3 Floor, Unisys Building, 650 Great South Road, Penrose, Auckland</ethicaddress>
      <ethicapprovaldate>11/09/2007</ethicapprovaldate>
      <hrec>NTX/07/03/025</hrec>
      <ethicsubmitdate>29/08/2007</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Alan Merry</name>
      <address>Department of Anaethesiology
University of Auckland
Private Bag 92019
Auckland</address>
      <phone>+64 9 6236588 ext 28443</phone>
      <fax>+64 9 6236587</fax>
      <email>a.merry@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Hartley Atkinson</name>
      <address>Po Box 33-203
Takapuna
Auckland</address>
      <phone>+64 9 4880232</phone>
      <fax>+64 9 4880234</fax>
      <email>hartley@aftpharm.com</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jennifer Zhang</name>
      <address>PO Box 33-203, Takapuna, Auckland</address>
      <phone>+ 64 9 4880232 ext 710</phone>
      <fax>+ 64 9 4880234</fax>
      <email>jennifer@aftpharm.com</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Alan Merry</name>
      <address>Department of Anaethesiology University of Auckland Private Bag 92019 Auckland</address>
      <phone>+64 9 6236588 ext 28443</phone>
      <fax />
      <email>a.merry@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>